Hepatitis D

Thermally Conductive Polymers Market to Surpass US$ 366.4 Million by 2030 - Coherent Market Insights

Retrieved on: 
Tuesday, November 14, 2023

BURLINGAME, Calif., Nov. 14, 2023 /PRNewswire/ -- According to Coherent Market Insights, Global Thermally Conductive Polymers Market size was valued at US$ 136.9 Million in 2022 and is expected to surpass US$ 366.4 Million by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 13.1% from 2023 to 2030.

Key Points: 
  • BURLINGAME, Calif., Nov. 14, 2023 /PRNewswire/ -- According to Coherent Market Insights, Global Thermally Conductive Polymers Market size was valued at US$ 136.9 Million in 2022 and is expected to surpass US$ 366.4 Million by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 13.1% from 2023 to 2030.
  • Furthermore, development of hybrid electric vehicles (HEV) and electric vehicles (EV) is augmenting demand for thermally conductive polymers from automotive industry, thereby propelling market growth.
  • Key Trends and Analysis of the Global Thermally Conductive Polymers Market:
    Adoption of EVs is a latest in the global thermally conductive polymers market.
  • Thermally conductive polymers have potential application in battery-powered vehicles due to their high energy density.

Thermally Conductive Polymers Market to Surpass US$ 366.4 Million by 2030 - Coherent Market Insights

Retrieved on: 
Tuesday, November 14, 2023

BURLINGAME, Calif., Nov. 14, 2023 /PRNewswire/ -- According to Coherent Market Insights, Global Thermally Conductive Polymers Market size was valued at US$ 136.9 Million in 2022 and is expected to surpass US$ 366.4 Million by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 13.1% from 2023 to 2030.

Key Points: 
  • BURLINGAME, Calif., Nov. 14, 2023 /PRNewswire/ -- According to Coherent Market Insights, Global Thermally Conductive Polymers Market size was valued at US$ 136.9 Million in 2022 and is expected to surpass US$ 366.4 Million by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 13.1% from 2023 to 2030.
  • Furthermore, development of hybrid electric vehicles (HEV) and electric vehicles (EV) is augmenting demand for thermally conductive polymers from automotive industry, thereby propelling market growth.
  • Key Trends and Analysis of the Global Thermally Conductive Polymers Market:
    Adoption of EVs is a latest in the global thermally conductive polymers market.
  • Thermally conductive polymers have potential application in battery-powered vehicles due to their high energy density.

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Retrieved on: 
Wednesday, November 8, 2023

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond

Key Points: 
  • Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.
  • We believe that the financial and scientific resources provided by the collaboration position us well to reach critical short- and long-term milestones and deliver value for patients and our shareholders.
  • Partnership includes Gilead opt-in rights on Assembly Bio’s current and future pipeline candidates, including two contributed Gilead herpesvirus programs.
  • Cash, cash equivalents and marketable securities were $46.2 million as of September 30, 2023, compared to $59.8 million as of June 30, 2023.

Usage Based Insurance Market worth $80.7 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, October 13, 2023

Battery electric vehicles (BEVs) are equipped with various sensors that generate data about vehicle usage, such as speed, mileage, braking patterns, and battery usage.

Key Points: 
  • Battery electric vehicles (BEVs) are equipped with various sensors that generate data about vehicle usage, such as speed, mileage, braking patterns, and battery usage.
  • North America has UBI's top key players: Allstate Insurance Company, Farmers Insurance, Nationwide Mutual Insurance Company, Progressive Casualty Insurance Company, State Farm Mutual Automobile Insurance Company, etc.
  • The usage-based insurance companies in North America, are UnipolSai Assicurazioni S.p.A (Italy), Progressive Casualty Insurance Company (US), Allstate Insurance Company (US), State Farm Automobile Mutual Insurance Company (US), and Liberty Mutual Insurance Company (US).
  • In July 2021, Unipol's Linear Assicurazioni and Cambridge Mobile Telematics (CMT) launched Italy's first try-before-you-buy auto insurance program.

Usage Based Insurance Market worth $80.7 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, October 13, 2023

Battery electric vehicles (BEVs) are equipped with various sensors that generate data about vehicle usage, such as speed, mileage, braking patterns, and battery usage.

Key Points: 
  • Battery electric vehicles (BEVs) are equipped with various sensors that generate data about vehicle usage, such as speed, mileage, braking patterns, and battery usage.
  • North America has UBI's top key players: Allstate Insurance Company, Farmers Insurance, Nationwide Mutual Insurance Company, Progressive Casualty Insurance Company, State Farm Mutual Automobile Insurance Company, etc.
  • The usage-based insurance companies in North America, are UnipolSai Assicurazioni S.p.A (Italy), Progressive Casualty Insurance Company (US), Allstate Insurance Company (US), State Farm Automobile Mutual Insurance Company (US), and Liberty Mutual Insurance Company (US).
  • In July 2021, Unipol's Linear Assicurazioni and Cambridge Mobile Telematics (CMT) launched Italy's first try-before-you-buy auto insurance program.

VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Retrieved on: 
Wednesday, July 19, 2023

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the Netherlands and Belgium for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the Netherlands and Belgium for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.
  • It can be expected that hepatitis D will also be prevented by immunization with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
  • As part of the marketing and distribution partnership announced in September 2022, PreHevbri will be available in the Netherlands and Belgium through Valneva’s existing commercial infrastructure and distribution networks.
  • Jeff Baxter, President and CEO of VBI, commented: “We are excited to announce the launch of PreHevbri in the Netherlands and Belgium through our partnership with Valneva.

Advancing Research, Awareness, Screening and Linkage to Care to Eliminate Hep D in the U.S. is Critical

Retrieved on: 
Tuesday, June 27, 2023

FAIRFIELD, N.J., June 27, 2023 /PRNewswire/ -- In a newly published article in the open journal, Hepatology Communications, the authors outline five urgent priority areas to address hepatitis delta (HDV)—the most aggressive form of viral hepatitis. The recommendations offered in "Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S." were the result of an American Liver Foundation and Hepatitis B Foundation joint roundtable on Hep D held in May 2022, and call on lawmakers to identify the unmet needs of this patient population and suggest strategies to better support and engage the larger community around the prevention, diagnosis, and management of hepatitis delta.

Key Points: 
  • The recommendations offered in " Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S ."
  • The five priority areas identified in the article are to generate accurate prevalence data, increase awareness, simplify screening and testing, facilitate research on linkage to care and follow-up and improve communication and outreach.
  • "It remains an enigma in the eyes of the public, healthcare providers, community groups and policy makers and that must change."
  • "This publication focuses on additional needs that must also be addressed to more optimally serve this neglected patient population."

VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Retrieved on: 
Thursday, June 15, 2023

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the United Kingdom (“U.K.”) for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the United Kingdom (“U.K.”) for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.
  • It can be expected that hepatitis D will also be prevented by immunization with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
  • As part of the marketing and distribution partnership announced in September 2022, PreHevbri will be available in the U.K. through Valneva’s existing commercial infrastructure and distribution networks.
  • Jeff Baxter, President and CEO of VBI, commented: “We are delighted to announce the availability of PreHevbri in the U.K., marking the first European market launch of our 3-antigen hepatitis B vaccine, which builds upon the increasing momentum for use in the U.S. (available under the brand name PreHevbrio®).

WPIC: Platinum deficit of 983 koz now forecast for 2023 as stronger-than-expected demand growth outstrips constrained supply

Retrieved on: 
Monday, May 15, 2023

Global platinum demand in the first quarter of 2023 jumped 28% (+441 koz) as an upswing in investment demand added to strong demand growth momentum in the automotive and industrial sectors.

Key Points: 
  • Global platinum demand in the first quarter of 2023 jumped 28% (+441 koz) as an upswing in investment demand added to strong demand growth momentum in the automotive and industrial sectors.
  • The result will mean net investment demand of 433 koz in 2023 – a swing of 1,073 koz on 2022.
  • Industrial platinum demand grew 8% (+43 koz) in Q1'23, driven by growth in chemical demand of 108% (+123 koz) due to paraxylene capacity additions in China.
  • With both issues likely to prevail throughout 2023, full year platinum recycling supply is forecast to fall by 1% (-9 koz) to 1,682 koz.

Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023

SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will highlight the Company’s expected 2023 catalysts and long-term growth strategy at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, at 9:45 a.m. PT / 12:45 p.m. ET.

Key Points: 
  • – Critical Phase 2 readouts anticipated in 2023 for three advanced programs – hepatitis B, hepatitis D and influenza –
    SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will highlight the Company’s expected 2023 catalysts and long-term growth strategy at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, at 9:45 a.m. PT / 12:45 p.m.
  • ET.
  • A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.